Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute promyelocytic leukaemia Age: Adult |
Dose: Oral – 45 mg/m2 Frequency: daily in 2 divided doses Duration: Treatment is continued until 30 days after complete remission or up to 90 days, whichever occurs first |
|
Indication: Acute promyelocytic leukaemia Age: Adult Condition: Hepatic impairment |
Dose: Oral – 25 mg/m2 Frequency: daily Note: Reduce dose to 25 mg/m2 daily in patients with hepatic impairment |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute promyelocytic leukaemia Age: 1-16 yr |
Dose: Oral – 45 mg/m2 Frequency: daily in 2 divided doses Duration: until 30 days after complete remission or up to 90 days, whichever occurs first |
|
Indication: Acute promyelocytic leukaemia Age: 1-16 yr Condition: Hepatic impairment |
Dose: Oral – 25 mg/m2 Frequency: daily |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not specified – 25 mg/m2 Frequency: daily Note: Reduce dose to 25 mg/m2 daily for renal impairment |
Administration
- Take with food
- Take exactly as prescribed
Side Effect
- Headache (86%)
- Fever (83%)
- Bone pain (77%)
- Dry mucous membranes (77%)
- Malaise (67%)
- URI (63%)
- Shivering (60%)
- Dyspnea (60%)
- Hemorrhage (60%)
- Elevated liver function tests (50-60%)
- Hyperlipidemia (60%)
- Infections (58%)
- Nausea and vomiting (57%)
- Rash (54%)
- Peripheral edema (52%)
- Leukocytosis (40%)
- Pain (37%)
- Abdominal pain (31%)
- DIC (26%)
- Respiratory insufficiency (26%)
- Mucositis (26%)
- GI disorder (26%)
- Retinoic acid-APL syndrome (25%)
- Ear ache (23%)
- Diarrhea (23%)
- Pleural effusion (20%)
- Dizziness (20%)
- Pruritus (20%)
- Sweating (20%)
- Anxiety (17%)
- Paresthesia (17%)
- Constipation (17%)
- Vision changes (17%)
- Dyspepsia (14%)
- Depression(14%)
- Insomnia (14%)
- Alopecia (14%)
- Skin changes (14%)
- Confusion (11%)
- Abdominal distention (11%)
- Renal insufficiency (11%)
- (selected) Cardiac failure
- Pseudotumor cerebri
- Ulcer
- Retinoic acid syndrome
- cardiac arrthythmia
- disseminated intravascular coagulation
- blood dyscrasias
- cardiac arrest
- cerebral haemorrhage
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Minoxidil
|
Enhances percutaneous absorption
|
|
Antifibrinolytic
|
Potentially Fatal: Increased risk of fatal thrombotic complications
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Eczematous Skin
|
Risk of severe skin irritation
|
|
Sunburnt/Abraded Skin
|
Risk of increased irritation
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 15° to 30°C. Protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.